ACTRN12609000788279已完成1 期
A Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-817399 in Healthy Subjects
Bristol-Myers Squibb0 个研究点目标入组 104 人开始时间: 2009年9月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 104
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Healthy subjects (men and women) having Body Mass Index (BMI) between 18 and 32 kg/m2
- •Women must not be of childbearing potential (i.e., who are postmenopausal or surgically sterile).
排除标准
- •Any significant acute or chronic medical illness.
- •Subjects at risk for tuberculosis (TB).
- •Evidence of organ dysfunction or any clinically significant deviation from normal.
- •Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) greater than 1.25 x upper normal limit (UNL) at screening.
研究者
相似试验
已完成
不适用
A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients with Molecularly Defined Genetic Muscular DystrophiesFacioscapulohumeral muscular dystrophygenetic myopathy10028396NL-OMON42284aTyr Pharma, Inc.16
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biological Activity of ATYR1940 in Adults with Genetic MyopathyFacioscapulohumeral muscular dystrophyMedDRA version: 17.1Level: PTClassification code 10064087Term: Facioscapulohumeral muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-001753-17-NLaTyr Pharma, Inc.20
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biological Activity of ATYR1940 in Adults with Genetic MyopathyFacioscapulohumeral muscular dystrophyMedDRA version: 17.0Level: PTClassification code 10064087Term: Facioscapulohumeral muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-001753-17-ITaTyr Pharma, Inc.20
招募中
1 期
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants with Myotonic Dystrophy Type 1Myotonic Dystrophy Type 1MedDRA version: 20.0Level: PTClassification code: 10068871Term: Myotonic dystrophy Class: 100000004850CTIS2023-510353-42-00Dyne Therapeutics Inc.79
进行中（未招募）
不适用
A Two-Stage Randomized Placebo-controlled Ascending Dose Phase I/ IIa Study to Evaluate Safety, Tolerability, Pharmacodynamic Effects and Preliminary Efficacy of an Anti-Interleukin 1 beta Vaccine (CYT013-IL1bQb) in Patients with Type 2 Diabetes Mellitus.adult patients with type 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2008-007012-15-DECytos Biotechnology AG122